2017 Drug Recall

Drug Name/Manufacturer	Dose/Package size	Press Release Date	Reason	Recall Classification
January				
Nadolol/Sandoz	40mg tablets	1/3/2017	Issued due to an out-of-specification result obtained relating to dissolution during routine stability testing.	Retail Level Recall
Donepezil/ Sky Pharma	10mg UD tablets	1/5/2017	Issued due to an out of specification result for assay test during routine stability testing	Retail Level Recall
Donepezil/ Sandoz	10mg tablets/ 1000ct and 30ct	1/4/2017	Issued due to an out of specification result for assay test during routine stability testing	Retail Level Recall
Albuterol Inhalation Solution/ Actavis	0.63mg/ 3mL x 25	1/13/2017	Issued due to the test results for related compound D (RC-D) that were slightly above specification (OOS) for the annual stability lot GA50370, expiration date 08-2016.	Retail Level Recall
Potassium Chloride/VistaPharm	20 mEq/15 mL	1/19/2017	Issued due to leakage that may occur at the seal. Consumption of a leaking product could result in a patient receiving a dose less than intended; opened containers could lead to potential contamination or the stability of the product could be in question	Retail Level Recall
Temozolomide capsules/ Mylan Pharmaceuticals	Temozolomide 100 mg capsules 14 count; Temozolomide 100 mg capsules 14 count; Temozolomide 100 mg capsules 5 count; Temozolomide 140 mg capsules 14 count; Temozolomide 140 mg capsules 5 count; Temozolomide 180 mg capsules 14 count; Temozolomide 180 mg capsules 5 count; Temozolomide 250 mg capsules 5 count	1/24/2017	Issued due to the potential of broken or crushed capsules resulting in loose powder in the bottle	Retail Level Recall
Vancomycin HCl/ Hospira	Injection/Carton containing 1x100mL vials	1/25/2017	A confirmed case of particulate matter discovered in a single vial.	Voluntary Recall
Venlafaxine HCl/ Aurobindo	37.5mg ER capsules	1/26/2017	Issued due to some of the bottles were found to contain clumped/melted capsules.	Retail Level Recall
Glipizide ER/ Actavis	2.5mg tablets	1/31/2017	Issued due to drug release results for Lot #3136782 being slightly above specification at one time point.	Retail Level Recall
February				
Fluconazole/ Dr. Reddy	Fluconazole 150 mg tablets 1 count; Fluconazole 200 mg tablets 30 Count; Fluconazole 50 mg tablets 30 count; Fluconazole 50 mg tablets 100 count; Fluconazole 100 mg tablets 30 count; Fluconazole 100 mg tablets 100 count; Fluconazole 200 mg tablets 100 count	2/2/2017	Issued due to an out-of-specification result obtained for Dissolution (tested with in-house Dissolution method with tighter specifications compared to USP method) during stability testing. Due to the out of specification Dissolution results, the desired therapeutic concentration of the drug may not be achieved at a particular time and thereby it may have effect on the drug action. However, since the product is found to comply with USP method, it is unlikely to have an impact on the efficacy of the Fluconazole tablets and the recall is being done as an abundant precaution.	Retail Level Recall
Transdermal Scopolamine Patch/ Sandoz	Patch	2/3/2017	Issued due to a discrepancy in the product labeling for the dispensing pouches and the outer carton	Retail Level Recall

Cyclosporine/ Apotex	100mg capsules	2/6/2017	Issued because the specified lot may not meet specification limit for the impurities throughout the shelf life of the product.	Retail Level Recall
Fluconazole/Major Pharmaceuticals.	100mg and 200mg UD tablets	2/7/2017	Issued due to an out of specification result obtained for dissolution during stability testing	Retail Level Recall
Fluconazole/Dr. Reddy's	Fluconazole 100 mg tablets 30 count, Fluconazole 100 mg tablets 100 count	2/8/2017	Issued due to failed dissolution specifications at the 18 month stability time point	Class II Recall
Fluconazole/ Dr. Reddy's	Fluconazole 50 mg tablets 30 count, Fluconazole 50mg tablets 100 count	2/8/2017	Issued due to failed dissolution specifications at the 18 month stability time point	Class II Recall
Fluconazole/ Dr. Reddy's.	150 mg tablets 12x1 Blister cards	2/8/2017	Issued due to failed dissolution specifications at the 18 month stability time point	Class II Recall
Levofloxacin/ Actavis.	Ophthalmic Solution 0.5 % 5 mL	2/8/2017	Issued due to the result for unknown related compounds (RC) being above specification for lot 633467 at the 18 month stability time point	Retail Level Recall
Glipizide ER tablets/ Actavis and distributed by American Health Packaging	Glipizide ER 2.5 mg UD tablets (carton); Glipizide ER 2.5 mg UD tablets	2/8/2017	Issued in support of the Activis recall which included lots that were repackaged by American Health Packaging dated January 30, 2017	Retail Level Recall
Buprenorphine/Naloxone/Teva	8mg/2mg tablets	2/8/2017	Issued due to our of specification test results for related compounds largest unknown impurity	Retail Level Recall
Carbidopa/Levodopa/ Sun	25mg/250mg tablets; 100 and 500 counts	2/8/2017	Issued due to failed dissolution specifications	Class II Recall
Ibuprofen lysine	20mg/2mL (10 mg/mL) vials; injection	2/10/2017	Issued due to particulate matter found in some of the vials.	Voluntary Recall
Clindamycin Phosphate and Benzoyl Peroxide Gel/ Perrigo	1.2%/5% gel; 45 g tubes	2/10/2017	Issued due to the presence of a small amount of mold on the caps of the tubes.	Voluntary Recall
Cyclosporine/ Apotex	100mg Capsules	2/13/2017	Issued because the specified lot may not meet specification limit for the impurities throughout the shelf life of the product	Retail Level Recall
Moxifloxacin HCl/ Dr. Reddy's	400mg tablets	2/13/2017	Issued due to high number of product complaints received for cracked and flaking coating of the tablets	Retail Level Recall
Cyclosporine/ Apotex: Repackaged by American Health Packaging	100mg capsules carton and unit dose	2/13/2017	Issued in support of the recall by Apotex which included a lot that was repackaged by American Health Packaging. Apotex stated that the lot may not meet specification limit for the impurities throughout the shelf life of the product	Retail Level Recall
Prevident 5000 Dry Mouth /Colgate Oral Pharmaceuticals	100mL	2/13/2017	Issued due to incorrect labeling on product packaging.	Retail Level Recall
Pioglitazone and Glimepiride HCl	Pioglitazone and Glimepiride HCl 30/2mg tablets; Pioglitazone and Glimepiride HCl 30/4mg tablets	2/14/2017	Issued due to an out-of-specification result obtained relating to dissolution during routine stability testing	Retail Level Recall
Metronidazole Injection/Hospira	500mg/100mL Injection	2/15/2017	Issued due to a confirmed customer report of a leaking bag	Retail Level Recall
Human Chorionic Gonadotropin (HCG)/ Synergy Rx Pharmacy	5000 units/vial and 11,000units/vial packaged in 15mL serum glass vials	2/15/2017	Issued due to lack of sterility assurance.	
Aspirin/Allegiant	81mg tablets	2/16/2017	Issued due to the potential for foreign material	Retail Level Recall
Zentane/ Dr. Reddy's	10, 20, 30 and 40 mg capsules	2/17/2017	Issued due to out of specification results for dissolution.	Retail Level Recall
Famciclovir/ AvKare	500mg tablets	2/17/2017	Issued due to an "out of spec" finding of related compounds	Retail Level Recall
Risedronate sodium/ Teva	35mg delayed release tablets	2/21/2017	Issued due to an out of specification result obtained during stability testing	Retail Level Recall
Aspirin/ McKesson Packaging Services	81mg Chewable Tablets	2/24/2017	Issued due to the discovery of foreign material in the bulk inventory	Retail Level Recall
A&D Zinc Oxide/ Bayer Healthcare	1.5oz, 3oz, 4oz creams	2/24/2017	Issued due to the current labeling including a claim the product is "phthalate-free". Bayer recently discovered that the product contains trace amounts of diethyl phthalate (DEP) due to a frangrance component utilized in product formulation.	Retail Level Recall
Penicillin V Potassium/ Citron Pharma	500mg tablets	2/24/2017	Issued due to more than a few bottles of 100 count products with different identification/imprints.	Retail Level Recall

Edex (alprostadil for injection)/ Endo International	10mcg, packaged in a 2 pack carton	2/24/2017	Recalled due to the detection by Endo of a defect in the crimp caps used in the manufacture of the subject product lot. This defect has the potential to lead to a loss of container closure integrity, which could impact the product's sterility assurance and may lead to serious adverse events such as infections, both localized at the site of injection and systemically. To date, Endo has not received adverse event reports related to this recall.	Voluntary Consumer-level Recall
Sterile injectable products labeled "latex-free"/ Advanced Pharma (now Avella Specialty Pharmacy)	N/A	2/27/2017	Sterile injectable products labeled "latex-free" may contain synthetic latex and/or natural latex	Voluntary Recall
March				
MakeSense PHARMA creams/ Cherry Hill Associates	MakeSense PHARMA, HEMORRHOIDAL RELIEF CREAM Phenylephrine HCL-0.25% Zinc Oxide-12.50%,1 oz. (28 g); MakeSense PHARMA FIRST AID CREAM Lidocaine HCL 0.5%, Phenol 0.5%, 1 oz. (28 g) tube; MakeSense PHARMA Medicated ANTI-ITCH CREAM WITH SOOTHING ALOE VERA AND VITAMIN E, Camphor-1% Menthol-1%, 1oz.(28 g) tube; MakeSense PHARMA ANTIFUNGAL CREAM 1 oz. Miconazole Nitrate 2%, 1 oz. (28 g) tube; MakeSense PHARMA ANTIFUNGAL CREAM Clotrimazole 1%, 1.25 oz. (35 g) tube	3/1/2017	Issued due to CGMP Deviations	Class II Recall
Transdermal Scopolamine/ Sandoz	1.5mg Single Patch	3/1/2017	Issued due to labeling, incorrect Instructions. The outer carton contains the incorrect instructions for Step 2 stating "Do cut the patch" rather than the correct instructions of "Do not cut the patch". The pouch containing the patch is labeled correctly	Class II Recall
Desonide/ Fougera	0.05% ointment	3/6/2017	Issued due to a packaging mix-up. The outer tube boxes are correctly labeled as Desonide Ointment 0.05% and contain the correct product insert; however, it is possible that some tube boxes may contain Desonide Ointment 0.05% labeled as Ketoconazole Cream 2%, 60g.	Retail Level Recall
Atenolol/ Zydus Pharmaceuticals	50mg tablets; 1,000 count and 100 count bottles	3/7/2017	Issued due to a single product complaint where the complainant found one tablet of Paroxetine 20mg Tablets in repackage bottle of Atenolol 50mg Tablets	Retail Level Recall
Curity Eye Pads and Dressings/ Medtronic	Curity Eye Pads Oval; Covidien Curity Eye Pad (Item 03201); Wet Dressing Saline; Covidien Curity Wet Dressing (Item 3337); Covidien Curity Sodium Chloride Dressing (Item 3339); Covidien Kerlix Super Sponge Saline Dressing (Item 3338);	3/7/2017	Issued due to the potential for the sterile packaging to be compromised.	Retail Level Recall
Calcipotriene/ Prasco	0.005% 60 gram and 0.005% 120 gram	3/8/2017	Issued due to the inadvertent omission of a drug excipient from the Authorized Generic Label and a warning regarding contact dermatitis from the brand product labeling not being incorporated into the Authorized Generic labeling.	Retail Level Recall
Indocin (indomethacin)/G&W Laboratories Inc.	50mg suppositories, USP	3/8/2017	Issued due to failed impurities/degradation specifications: out of specification (OOS) for total impurity and out of trend for known impurity results encountered during stability testing	Class II Recall

Alfuzosin Hydrochloride/ Sun Pharmaceutical Industries Ltd.	10mg tablets extended-release	3/8/2017	Issued due to presence of foreign substance: consumer complaint for foreign matter embedded in the tablet identified as a broken piece of wire rope from the manufacturing equipment.	Class II Recall
Duopa/ AbbVie Inc.	Duopa 4.63 mg/20 mg per mL, 100 mL cassette, 7 cassettes per carton	3/8/2017	Issued due to failed stability specifications confirmed out of specification results obtained during refrigerated material stability testing indicating that drug may settle within drug cassettes nearing the end of their refrigerated shelf-life.	Class II Recall
Quillivant XR/Pfizer	Quillivant XR Oral Suspension 750 mg 150 mL; Quillivant XR Oral Suspension 900 mg 180 mL; Quillivant XR Oral Suspension 300 mg 60 mL	3/8/2017	Issued due to product from lot 03215042A not meeting the specification for dissolution.	Retail Level Recall
Glipizide tablets/ Mylan Pharmaceuticals Inc.	5mg Extended-Release tablets	3/8/2017	Issued due to presence of foreign tablets/capsules. Bottles of Glipizide 5 mg tablets may contain Glipizide 10 mg tablets	Class II Recall
Eye Wash/ Major Pharmaceuticals	NDC# 00904-6491-20	3/8/2017	Issued due to due to microbial contamination. Use of a contaminated product could be calamitous for any population since there is a reasonable probability of a potentially sight-threatening eye infection.	Class 1 Recall
Ciprofloxacin/Calaris	2mg/mL 200mL IV bag	3/10/2017	Issued due to the potential of a leak from the primary container, which may have resulted from shipping damage and which may result in a potential breach of sterility and contamination of the contents	Retail Level Recall
Fluconazole/Calaris	400mg/200mL injection	3/10/2017	Issued due to the potential of a leak from the primary container, which may have resulted from shipping damage and which may result in a potential breach of sterility and contamination of the contents	Retail Level Recall
Levofloxacin/Calaris	750/150mL bag	3/10/2017	Issued due to the potential of a leak from the primary container, which may have resulted from shipping damage and which may result in a potential breach of sterility and contamination of the contents	Retail Level Recall
Metronidazole injection/Calaris	500mg/100mL bag	3/10/2017	Issued due to the potential of a leak from the primary container, which may have resulted from shipping damage and which may result in a potential breach of sterility and contamination of the contents	Retail Level Recall
Various Freeze Products/Perfecta	Max-Freeze Pain Relief Wipes UPC# 78148526002; Zims Lido-Freeze Roll On UPC# 78148525603; Zims Max-Freeze Extra Large Patch UPC# 78148526004; Zims Max-Freeze Large Patch UPC# 78148526003	3/14/2017	Issued the packaging of the products does not conform to the special child resistant and senior-friendly requirements of the Poison Prevention Packaging Act.	Retail Level Recall
Rivastigmine/ Dr. Reddy's	1.5mg DR capsules	3/15/2017	Issued due to the observation of Ranitidine levels higher than allowed during related substances test	Retail Level Recall
Pioglitazone and Glimepiride/ Sandoz Inc.	30mg/4mg tablets	3/15/2017	Issued due to failed dissolution specifications.	Class II Recall
Calcipotriene/Leo Pharma	0.0005% cream (60g tube and 120g tube)	3/15/2017	Issued due to incorrect/undeclared excipients. Inadvertent omission of a drug excipient from the Authorized Generic label and also a warning regarding contact dermatitis from the brand product labeling not being incorporated into the Authorized Generic labeling	Class II Recall
Sulfamethoxazole/Trimethoprim/Akorn	Oral Suspension	3/17/2017	Issued due to out of specification dissolution results for the sulfamethoxazole portion of the drug product.	Retail Level Recall
Divalproex Sodium / Zydus	500mg delayed release tablets	3/17/2017	Issued due to a failure observed during our long-term stability study point of nine months for the product.	Retail Level Recall
Testosterone Cypionate Injection/ Sun Pharmaceutical	200mg/mL 1mL vials	3/17/2017	Issued due to an identified black particulate (specks) adhered to the inside of some vials of Testosterone Cypionate Injection 200mg/mL, 1mL vial	Retail Level Recall
Fluphenazine/ Fresenius Kabi	25mg 5mL multi-dose vials	3/20/2017	Issued due to out of specification results for assay at the 13 month stability test for batch 6112346. As a precautionary measure the three additional lots which may also be OOS prior to expiry are also included in this recall	Retail Level Recall

Testosterone Cypionate Injection/ Sun Pharmaceutical	200mg/mL 1mL single-dose vials	3/21/2017	Issued due to black particulate (specks) adhered to the inside of some vials of Testosterone Cypionate Injection 200mg/mL, 1 mL vial	Class II Recall
Lumigan Opthalmic Solution/ Allergan	0.01% 7.5mL	3/21/2017	Issued due to product sample testing results that did not meet the regulatory specification for individual and total impurities	Retail Level Recall
Ventolin HFA/GlaxoSmithKline	200 dose inhaler	3/22/2017	Issued due to an elevated number of units with out of specification results for leak rate.	Retail Level Recall
Atorvastatin/Mylan Pharmaceuticals	10mg unit dose tablets	3/22/2017	Issued due to the potential of an elevated bioburden with identification of objectionable organisms	Retail Level Recall
Atorvastatin/Mylan Pharmaceuticals	10mg tablets; 90 count, 500 count. 20mg tablets; 90 count and 500 count. 40 mg tablets; 90 count and 500 count. 80mg tablets; 90 count and 500 count	3/22/2017	Issued due to the potential of an elevated bioburden with identification of objectionable organisms	Retail Level Recall
Mirtazapine/ Mylan Pharmaceuticals	45mg tablets; 30 count, 100 count, 500 count, unit-dose tablets 100 count	3/22/2017	Issued due to the possibility of Glipizide 10mg tablet in bottle	Class II Recall
Kalbitor/Shire	10mg/1mL vials	3/23/2017	Issued as a precautionary measure after receiving notification of particles discovered in retention samples	Patient-level Recall
Latanoprost/Akorn	0.005% eye drops	3/24/2017	Issued due to customer reports of underfulled and/or empty units	Retail Level Recall
PrednisoLONE oral suspension/ Teva Pharmaceuticals	PrednisoLONE oral suspension15mg/ 5mL	3/29/2017	Issued due to out of specification alcohol content test results obtained during stability testing	Retail Level Recall
Desoximetasone ointment /Akorn	Desoximetasone Ointment 0.25% 15 G and Desoximetasone Ointment 0.25% 60 G	3/30/2017	Issued due to a homogeneity/phase separation issue	Retail Level Recall
Pilocarpine/ Sandoz	4% eye drops	3/30/2017	Issued due to an out-of-specification result obtained for one of the known active ingredient degradant, Isopilocarpine.	Retail Level Recall
EpiPen and Epipen Jr/ Meridian Medical Technologies, a Pfizer company, and distributed by Mylan Specialty between December 2015 and July 2016	0.3 mg and 0.15 mg strengths of EpiPen Auto-Injector. None of the recalled lots include the authorized generic for EpiPen Auto-Injector	3/31/2017	This recall is being conducted as a result of the receipt of two previously disclosed reports outside of the U.S. of failure to activate the device due to a potential defect in a supplier component. The potential defect could make the device difficult to activate in an emergency (failure to activate or increased force needed to activate) and have significant health consequences for a patient experiencing a life-threatening allergic reaction (anaphylaxis).	Voluntary Recall
April				
Isopto® Carpine 4% /Alcon.	Eye Drops 15 mL bottle	4/5/2017	This recall was issued due to an out-of-specification result obtained for one of the known active ingredient degradants, Isopilocarpine, during stability testing.	Retail Level Recall
Various products/Claris Lifesciences Inc.	Ciprofloxacin in Dextrose (5%) Injection, USP, 400 mg in 200 mL 5% Dextrose. NDC #36000-009-24; Fluconazole Injection, USP, 400mg in 200mL NDC # 36000-0003-06. Levofloxacin Injection in 5% Dextrose, 750mg in 150mL 5% Dextrose NDC # 36000-0048-24and Metronidazole Injection, USP, 500mg/100mL NDC # 36000-0001-24	4/5/2017	Issued due to lack of assurance of sterility. There is potential of a leak from the primary container which may result in a potential breach of sterility and contamination of the product	Class II Recall
Hyland's Baby Teething Tablets & Hyland's Baby Nighttime Teething tablets/ Standard Homeopathic Company	Teething tablets	4/10/2017	The U.S. Food & Drug Administration (FDA) has concluded that the medicines have been found to contain inconsistent amounts of belladonna alkaloids that may differ from the calculated amount on the products' labels.	Nationwide voluntary recall

Ibuprofen lysine/ Exela Pharma Sciences	20mg/2mL single dose vials; injection. 20mg/2mL packaged in 3x2 mL single-dose vials per carton.	4/12/2017	FDA believes that belladonna represents a serious health hazard to children and that the effects of belladonna are unpredictable	Class I Recall
Cotellic (cobimetinib)/ Genentech Inc.	20mg tablets	4/12/2017	Issued due to super potent drug. An oversized tablet was found in a bottle.	Class II Recall
Vancomycin HCl for Injection/ Hospira	USP 10 grams 100 mL vial	4/12/2017	Issued due to the presence of particulate matter. A hair was found stuck to the stopper of inside a single vial. The hair came in contact with the reconstituted drug product. In the unlikely event that the particulate is administered to a patient, it may result in local swelling, irritation of blood vessels or tissue, blockage of blood vessels and/or low-level allergic response to the particulate. The risk is reduced by the possibility of detection, as the label contains a clear statement directing the physician to visually inspect the product for particulate matter and discoloration prior to administration.	Class I Recall
Alfuzosin Hydrochloride/ Sun Pharma	10mg ER tablets	4/13/2017	Issued due to a market complaint of foreign matter in one tablet.	Retail Level Recall
APEX 26-Lead Transfer Set/ B Braun	APEX 26-Lead Transfer Set	4/13/2017	Issued due to the potential for internal leaking at the macro valves of APEX 26-lead transfer set in small percentage (.11%) of product.	Retail Level Recall
Hydralazine HCl Injection/McKesson Medical-Surgical Inc.	20mg/mL 1mL single-dose vial	4/19/2017	Issued due to temperature abuse. Certain pieces of these lots distributed by McKesson Medical Surgical Inc. were inadvertently stored refrigerated rather than the labeled room temperature recommendation.	Class II Recall
Riomet solution/Sun Pharma	500mg/5mL solution 473mL; 500mg/5mL solution 118mL	4/21/2017	Issued due to Sun Pharma has identified a microbial contaminant (Scopulariopsis Brevicaulis) in one bottle of Metformin Hydochloride Oral Solution 500mg in 5 mL during preparation for anti-microbial effectiveness testing in February 2017 as part of the long term stability program.	Retail Level Recall
Phenobarbital/ C.O. Truxton, Inc	15mg tablets 1000 count bottles, NDC 0463-6160-10, UPC 7 0463616010 6,	4/21/2017	The manufacturer received a confirmed customer complaint that a bottle labeled as phenobarbital 15 mg was found to contain phenobarbital 30 mg tablets.	Voluntary Recall
Dextrose	25% pre-filled 10 mL syringes manufactured by Hospira	4/24/2017	This recall was issued due to the presence of particulate matter, identified as human hair, found within an internal sample syringe.	Voluntary Recall
Healon	OVD solutions manufactured by Abbott Medical Optics	4/25/2017	This recall was issued due to a remote possibility that exists that certain Healon OVD solutions in the affected lots may contain microscopic glass particles due to damage that occurred at the cylinder neck during the manufacturing process.	Voluntary Recall
Nystatin and Triamcinolone Acetonide Cream	100,000/1 mg manufactured by Taro Pharmaceuticals	4/26/2017	This recall was issued due to failed content uniformity specifications; out-of-specification (OOS) results 18-month stability	Class II Recall
Clozapine	25 mg Tablets	4/25/2017	This recall was issued to the presence of mold that was identified in a customer sample of once distributed bottle	Voluntary Recall
May				
Buprenorphine HCl Injection	0.3 mg/mL	5/3/2017	This recall was issued due to the potential for the presence of white, crystalline particulates which are comprised of component or components of the drug product formulation, principally desxtrose and the buprenorphine active component.	Voluntary Recall
Amitriptyline HCL Tablets	USP 50mg	5/8/2017	Truxton has not received any complaints for the products listed below - however, due to the initial recall resulting from a label mix-up error, out of an abundance of caution, we are recalling all products that were repackaged into a Truxton Incorporated label.	Voluntary Recall
Phenobarbital Tablets	USP 15mg, 30mg, 60mg, 100mg	5/8/2017	Truxton has not received any complaints for the products listed below - however, due to the initial recall resulting from a label mix-up error, out of an abundance of caution, we are recalling all products that were repackaged into a Truxton Incorporated label.	Voluntary Recall
Divalproex Sodium	125 mg delayed release tablets	5/12/2017	This recall was issued due to a failure observed during a long-term stability study point of nine months for the product.	Voluntary Recall
Divalproex Sodium	250 mg delayed release tablets	5/12/2017	This recall was issued due to a failure observed during a long-term stability study point of nine months for the product.	Voluntary Recall
Divalproex Sodium	250 mg delayed release tablets	5/12/2017	This recall was issued due to a failure observed during a long-term stability study point of nine months for the product.	Voluntary Recall
Divalproex Sodium	500 mg delayed release tablets	5/12/2017	This recall was issued due to a failure observed during a long-term stability study point of nine months for the product.	Voluntary Recall
Divalproex Sodium	500 mg delayed release tablets	5/12/2017	This recall was issued due to a failure observed during a long-term stability study point of nine months for the product.	Voluntary Recall

Buprenorphine HCl Injection	0.3 mg/mL	5/17/2017	This recall was issued due to the potential for the presence of white, crystalline particulates which are comprised of component or components of the drug product formulation, principally desxtrose and the buprenorphine active component.	Level II
Mibelas 24 FE	1/.02 mg tablets	5/17/2017	This recall was issued due to a packaging error, where one blister was rotated 180 degrees within the wallet, reversing the weekly tablet orientation and making the lot number and expiry date no longer visible.	Voluntary Recall
Levophed Injection	1 mg/ mL 4 mL	5/19/2017	This recall was issued due to the potential for a foreign stopper, which is not used by the Hospira McPherson site, to have been used during filling of vials.	Voluntary Recall
Saphris® Sublingual Black Cherry	10 mg tablets, 6 shell packs & 1 Blister Card pack.	5/19/2017	This recall was issued due to blister debossing not matching the blister lidding foil and shell-pack.	Voluntary Recall
Fluconazole Injection	200 mg/100 mL (2mg/mL), 100 mL Single-Dose Intravia Container bag	5/24/2017	This recall was issued due to lack of assurance of sterility: customer complaints received for the presence of leaks.	Voluntary Recall
Milrinone Lactate in 5% Dextrose Injection	20 mg/100 mL, 100 mL Single-Dose Intravia Container bag	5/24/2017	This recall was issued due to lack of assurance of sterility: customer complaints received for the presence of leaks.	Voluntary Recall
Zenatane Capsules	10mg, 20mg, 30mg, 40mg Capsules	5/24/2017	This recall was issued was initiated due to an out-of-specification result that was observed for Dissolution in batch KB60254.	Voluntary Recall
Brilinta	90 mg Professional Sample Bottles	5/24/2017	This voluntary recall follows a report that a professional sample bottle containing eight tablets of BRILINTA 90mg also contained another medicine called ZURAMPIC® (lesinurad) 200 mg tablets which is also manufactured by AstraZeneca.	Voluntary Recall
Mibelas 24 Fe	(Norethindrone Acetate and Ethinyl Estradiol 1 mg/0.02 mg chewable and ferrous fumarate 75 mg)	5/25/2017	A confirmed market complaint indicated a packaging error, where the blister was rotated 180 degrees within the wallet, reversing the weekly tablet orientation and making the lot number and expiration date no longer visible.	Voluntary Recall
MibelasTM 24 FE	1 mg/0.02 mg tablets 3 x 28, 1 mg/0.02 mg tablets (Individual Wallet)	5/26/2017	This recall was issued due to a packaging error, where one blister was rotated 180 degrees within the wallet, reversing the weekly tablet orientation and making the lot number and expiry date no longer visible.	Voluntary Recall
Brilinta (ticagrelor)	90mg Tablets	5/26/2017	AstraZeneca announced a voluntary recall of 1 lot of professional (physician) sample bottles containing Brilinta (ticagrelor) 90mg tablets as a precaution after a report showed the sample bottle contained Brilinta 90mg and Zurampic (lesinurad) 200mg tablets.	Voluntary Recall
BD Insulin Syringes with the BD Ultra-FineTM needle	½ Ml 12.7 mm 30G	5/26/2017	This recall was issued because some polybags in the lot are incorrectly labeled as BD Ultra-FineTM needle 1/2 mL 8 mm x 31G.	Voluntary Recall
IC-Green Kit	25 mg injection	5/30/2017	This recall was issued due to low pH value in the product.	Voluntary Recall
Dextrose	25% pre-filled 10 mL syringes manufactured by Hospira	5/31/2017	This recall was issued due to the presence of particulate matter, identified as human hair, found within an internal sample syringe.	Class 1 Recall
Dextrose	25% pre-filled 10 mL syringe	5/31/2017	This recall was issued due to the presence of particulate matter, identified as human hair, found within an internal sample syringe.	Class 1 Recall
Shield and Protect Moisture Barrier Cream 1.1% Clotrimazole	Cream	5/31/2017	This recall was issued because product may not meet cGMP requirements.	Voluntary Recall
Alprazolam	Extended-Release 1 mg tablets	5/31/2017	This recall was issued due to failed dissolution specifications.	Voluntary Recall
Estriol for Prescription Compounding	1 G bottle	5/31/2017	This recall was issued due to a lack of quality assurance at the API manufacturer.	Voluntary Recall
Estriol for Prescription Compounding	5 G bottle	5/31/2017	This recall was issued due to a lack of quality assurance at the API manufacturer.	Voluntary Recall
Estriol for Prescription Compounding	25 G bottle	5/31/2017	This recall was issued due to a lack of quality assurance at the API manufacturer.	Voluntary Recall
Estriol for Prescription Compounding	100 G bottle	5/31/2017	This recall was issued due to a lack of quality assurance at the API manufacturer.	Voluntary Recall
Estriol for Prescription Compounding	100 G bottle	5/31/2017	This recall was issued due to a lack of quality assurance at the API manufacturer.	Voluntary Recall

Estrone for Prescription Compounding	1 G bottle	5/31/2017	This recall was issued due to a lack of quality assurance at the API manufacturer.	Voluntary Recall
Estrone for Prescription Compounding	5 G bottle	5/31/2017	This recall was issued due to a lack of quality assurance at the API manufacturer.	Voluntary Recall
Estrone for Prescription Compounding	25 G bottle	5/31/2017	This recall was issued due to a lack of quality assurance at the API manufacturer.	Voluntary Recall
Estrone for Prescription Compounding	100 G bottle	5/31/2017	This recall was issued due to a lack of quality assurance at the API manufacturer.	Voluntary Recall
Estrone for Prescription Compounding	1 G bottle	5/31/2017	This recall was issued due to a lack of quality assurance at the API manufacturer.	Voluntary Recall
Estrone for Prescription Compounding	5 G bottle	5/31/2017	This recall was issued due to a lack of quality assurance at the API manufacturer.	Voluntary Recall
Estrone for Prescription Compounding	25 G bottle	5/31/2017	This recall was issued due to a lack of quality assurance at the API manufacturer.	Voluntary Recall
Estrone for Prescription Compounding	100 G bottle	5/31/2017	This recall was issued due to a lack of quality assurance at the API manufacturer.	Voluntary Recall
June				
Paliperidone	extended-release 3 mg tablets	6/1/2017	This recall was issued due to a dissolution test result, obtained during 9-month stability testing, which was below specification for one tablet and the potential for some tablets to be below specification.	Voluntary Recall
Bupropion HCl	150 mg tablets	6/2/2017	This recall was issued due to the discovery of Out-of-Specification for moisture content.	Voluntary Recall
Bupropion HCl	75 mg Tablets	6/2/2017	This recall was issued due to the discovery of Out-of-Specification for moisture content.	Voluntary Recall
Optic Splash Eye Drops	15mL	6/6/2017	This recall was issued due to a lack of assurance of sterility.	Voluntary Recall
SATO CLEAR Redness Reliever Eye Drops	15mL	6/6/2017	This recall was issued due to a lack of assurance of sterility.	Voluntary Recall
DORAMA-NEO Eye wash	15mL	6/6/2017	This recall was issued due to a lack of assurance of sterility.	Voluntary Recall
Eliquis	5mg tablets	6/7/2017	This recall was issued due to the company's investigation of one field complaint of a single Eliquis 5 mg strength bottle containing lower-strength 2.5 mg tablets.	Voluntary Recall
Venlafaxine HCl ER	75 mg capsules 30 count	6/7/2017	This recall was issued due to melted capsules found in multiple bottles.	Voluntary Recall
Venlafaxine HCl ER	75 mg capsules 90 count	6/7/2017	This recall was issued due to melted capsules found in multiple bottles.	Voluntary Recall
Clobetasol Propionate Ointment	15gm	6/8/2017	This recall was issued due to an out of specification impurity result.	Voluntary Recall
Clobetasol Propionate Ointment	30gm	6/8/2017	This recall was issued due to an out of specification impurity result.	Voluntary Recall
Clobetasol Propionate Ointment	45gm	6/8/2017	This recall was issued due to an out of specification impurity result.	Voluntary Recall
Clobetasol Propionate Ointment	60gm	6/8/2017	This recall was issued due to an out of specification impurity result.	Voluntary Recall
Eliquis	5mg tablets	6/6/2017, 6/8/2017, 6/13/2017	This recall was issued due to the company's investigation of one field complaint of a single Eliquis 5 mg strength bottle containing lower-strength 2.5 mg tablets.	Voluntary Consumer-level Recall
NasalCrom® Nasal Allergy Spray	Spray	6/9/2017, 6/14/2017	This recall was issued due to the possibility of the presence of a microbial contamination in the water used to manufacture this lot of product.	Voluntary Recall
Alprazolam ER	1mg Tablets	6/13/2017	This recall was issued due to failed dissolution specifications.	Class II Recall
Option 2, Levonorgestrel Tablet	1.5 mg, Emergency Contraceptive, 1 Tablet per box	6/14/2017	This recall was issued due to a defective container. A carton is missing the tablet blister strip and tablet.	Class II Recall

Paliperidone	Extended-release 3 mg, 90 count tablets	6/15/2017	This recall was issued due to failing test results for dissolution. Teva cannot at this time exclude the potential for additional tablets to be below specification. Please note: This recall was originally issued on June 2, 2017 to the retail-level. Teva elevated this recall to the consumer-level on June 15, 2017.	Voluntary Consumer-level Recall
Sodium Bicarbonate Injection	50mL vials	6/16/2017	The recall was instigated after a microbial growth was discovered in the manufacturing process. **Secondary recall issued 6/22/2017** - Recall due to Hospira Inc.'s ("Hospira") June 15, 2017 recall announcement that microbial growth was detected during a routine simulation of the manufacturing process and therefore there was a lack of sterility assurance. Link: https://www.fda.gov/Safety/Recalls/ucm564300.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery	Retail Level Recall
Neut	(sodium bicarbonate 4% additive solution), 5mL vials	6/16/2017	The recall was instigated after a microbial growth was discovered in the manufacturing process. **Secondary recall issued 6/22/2017** - Recall due to Hospira Inc.'s ("Hospira") June 15, 2017 recall announcement that microbial growth was detected during a routine simulation of the manufacturing process and therefore there was a lack of sterility assurance. Link: https://www.fda.gov/Safety/Recalls/ucm564300.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery	Retail Level Recall
Quelicin	(succinylcholine chloride injection), 200mg/10mL vials	6/16/2017	The recall was instigated after a microbial growth was discovered in the manufacturing process. **Secondary recall issued 6/22/2017** - Recall due to Hospira Inc.'s ("Hospira") June 15, 2017 recall announcement that microbial growth was detected during a routine simulation of the manufacturing process and therefore there was a lack of sterility assurance. Link: https://www.fda.gov/Safety/Recalls/ucm564300.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery	Retail Level Recall
Potassium Phosphates	Injection, 45mM vials	6/16/2017	The recall was instigated after a microbial growth was discovered in the manufacturing process. **Secondary recall issued 6/22/2017** - Recall due to Hospira Inc.'s ("Hospira") June 15, 2017 recall announcement that microbial growth was detected during a routine simulation of the manufacturing process and therefore there was a lack of sterility assurance. Link: https://www.fda.gov/Safety/Recalls/ucm564300.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery	Retail Level Recall
Nitroglycerin	Injection 5% Dextrose USP - 100mcg per mL and 200mcg per mL strengths available in 5mL, 10mL, and 20mL sterile single dose syringes	6/16/2017	Advanced Pharma Inc. d/b/a Avella of Houston is recalling all unexpired lots of Nitroglycerin Injection 5% Dextrose USP products due to a lower than expected potency. The recalled products were produced at their Houston location between March 3 and May 31, 2017.	Retail Level Recall
Clindamycin Injection USP ADD	Vantage Vials	6/16/2017	Alvogen is voluntarily recalling seven lots of Clindamycin Injection USP ADD-Vantage Vials to the hospital/retail level due to microbial growth detected during a routine simulation of the manufacturing process, which represents the potential introduction of microorganisms into the product.	Voluntary Recall
Amitriptyline	25 mg, 100 count	6/20/2017	This recall was issued due to the presence of an unrelated active ingredient, Imipramine, which was identified during routine testing.	Retail Level Recall
Amitriptyline	25 mg, 1000 count	6/20/2017	This recall was issued due to the presence of an unrelated active ingredient, Imipramine, which was identified during routine testing.	Retail Level Recall
Ibuprofen	600 mg Tablets, 500 Count	6/20/2017	This recall was issued because it may contain Ibuprofen Tablets USP 800 mg. The recall involves only the 500 count bottles.	Retail Level Recall
ESTRONE USP for Prescription Compounding	1g Bottle	6/21/2017	This recall was issued due to cGMP Deviations; lack of quality assurance.	Class II Recall
ESTRONE USP for Prescription Compounding	5g Bottle	6/21/2017	This recall was issued due to cGMP Deviations; lack of quality assurance.	Class II Recall
ESTRONE USP for Prescription Compounding	25g Bottle	6/21/2017	This recall was issued due to cGMP Deviations; lack of quality assurance.	Class II Recall

Succinylcholine Chloride	20mg/mL 5mL syringe	6/23/2017	The secondary recall of product manufactured by Hospira Inc., a Pfizer company, and repacked by Fagron Sterile Services is due to microbial growth detected during a routine simulation of Hospira's manufacturing process, which represents the potential introduction of microorganisms into the product. To date, there have been no reports of adverse events. This secondary recall is being conducted as result of the recall initiated by the manufacturer on June 15, 2017 https://www.fda.gov/Safety/Recalls/ucm563383.htm.	Voluntary Recall
NasalCrom Allergy Spray	0.44 oz	6/26/2017	This recall was issued due to the possibility of the presence of a microbial contamination in the water used to manufacture this lot of product.	Retail Level Recall
Potassium Phosphate	10 mMol Potassium Phosphate (Preservative Free) in 0.9% Sodium Chloride 250 mL in 250 mL Intravia Bag	6/26/2017	PharMEDium Services is conducting a limited, voluntary recall due to Hospira Inc.'s ("Hospira") June 15, 2017 recall announcement that microbial growth was detected during a routine simulation of the manufacturing process and therefore there was a lack of sterility assurance. The products being recalled by PharMEDium Services were compounded using certain Hospira products. The recalled products are specific lots of Potassium Phosphate and Succinylcholine Chloride. This is a secondary recall based on a Hospira's recent recall: https://www.fda.gov/Safety/Recalls/ucm563383.htm.	Voluntary Recall
Potassium Phosphate	15 mMol Potassium Phosphate (Preservative Free) in 0.9% Sodium Chloride 250 mL in 250 mL Intravia Bag	6/26/2017	PharMEDium Services is conducting a limited, voluntary recall due to Hospira Inc.'s ("Hospira") June 15, 2017 recall announcement that microbial growth was detected during a routine simulation of the manufacturing process and therefore there was a lack of sterility assurance. The products being recalled by PharMEDium Services were compounded using certain Hospira products. The recalled products are specific lots of Potassium Phosphate and Succinylcholine Chloride. This is a secondary recall based on a Hospira's recent recall: https://www.fda.gov/Safety/Recalls/ucm563383.htm.	Voluntary Recall
Potassium Phosphate	30 mMol Potassium Phosphate (Preservative Free) in 5% Dextrose 500 mL in 500 mL Intravia Bag	6/26/2017	PharMEDium Services is conducting a limited, voluntary recall due to Hospira Inc.'s ("Hospira") June 15, 2017 recall announcement that microbial growth was detected during a routine simulation of the manufacturing process and therefore there was a lack of sterility assurance. The products being recalled by PharMEDium Services were compounded using certain Hospira products. The recalled products are specific lots of Potassium Phosphate and Succinylcholine Chloride. This is a secondary recall based on a Hospira's recent recall: https://www.fda.gov/Safety/Recalls/ucm563383.htm.	Voluntary Recall
Potassium Phosphate	7 mMol Potassium Phosphate (Preservative Free) in 0.9% Sodium Chloride 100 mL in 150 mL Intravia Bag	6/26/2017	PharMEDium Services is conducting a limited, voluntary recall due to Hospira Inc.'s ("Hospira") June 15, 2017 recall announcement that microbial growth was detected during a routine simulation of the manufacturing process and therefore there was a lack of sterility assurance. The products being recalled by PharMEDium Services were compounded using certain Hospira products. The recalled products are specific lots of Potassium Phosphate and Succinylcholine Chloride. This is a secondary recall based on a Hospira's recent recall: https://www.fda.gov/Safety/Recalls/ucm563383.htm.	Voluntary Recall
Potassium Phosphate	30 mMol Potassium Phosphate (Preservative Free) in 0.9% Sodium Chloride 500 mL in 500 mL Intravia Bag	6/26/2017	PharMEDium Services is conducting a limited, voluntary recall due to Hospira Inc.'s ("Hospira") June 15, 2017 recall announcement that microbial growth was detected during a routine simulation of the manufacturing process and therefore there was a lack of sterility assurance. The products being recalled by PharMEDium Services were compounded using certain Hospira products. The recalled products are specific lots of Potassium Phosphate and Succinylcholine Chloride. This is a secondary recall based on a Hospira's recent recall: https://www.fda.gov/Safety/Recalls/ucm563383.htm.	Voluntary Recall
Potassium Phosphate	9 mMol Potassium Phosphate (Preservative Free) in 0.9% Sodium Chloride 100 mL in 150 mL Intravia Bag	6/26/2017	PharMEDium Services is conducting a limited, voluntary recall due to Hospira Inc.'s ("Hospira") June 15, 2017 recall announcement that microbial growth was detected during a routine simulation of the manufacturing process and therefore there was a lack of sterility assurance. The products being recalled by PharMEDium Services were compounded using certain Hospira products. The recalled products are specific lots of Potassium Phosphate and Succinylcholine Chloride. This is a secondary recall based on a Hospira's recent recall: https://www.fda.gov/Safety/Recalls/ucm563383.htm.	Voluntary Recall

Potassium Phosphate	20 mMol Potassium Phosphate (Preservative Free) in 0.9% Sodium Chloride 100 mL in 150 mL Intravia Bag	6/26/2017	PharMEDium Services is conducting a limited, voluntary recall due to Hospira Inc.'s ("Hospira") June 15, 2017 recall announcement that microbial growth was detected during a routine simulation of the manufacturing process and therefore there was a lack of sterility assurance. The products being recalled by PharMEDium Services were compounded using certain Hospira products. The recalled products are specific lots of Potassium Phosphate and Succinylcholine Chloride. This is a secondary recall based on a Hospira's recent recall: https://www.fda.gov/Safety/Recalls/ucm563383.htm.	Voluntary Recall
Potassium Phosphate	10 mMol Potassium Phosphate (Preservative Free) in 0.9% Sodium Chloride 100 mL in 150 mL Intravia Bag	6/26/2017	PharMEDium Services is conducting a limited, voluntary recall due to Hospira Inc.'s ("Hospira") June 15, 2017 recall announcement that microbial growth was detected during a routine simulation of the manufacturing process and therefore there was a lack of sterility assurance. The products being recalled by PharMEDium Services were compounded using certain Hospira products. The recalled products are specific lots of Potassium Phosphate and Succinylcholine Chloride. This is a secondary recall based on a Hospira's recent recall: https://www.fda.gov/Safety/Recalls/ucm563383.htm.	Voluntary Recall
Potassium Phosphate	30 mMol Potassium Phosphate (Preservative Free) in 0.9% Sodium Chloride 250 mL in 250 mL Intravia Bag	6/26/2017	PharMEDium Services is conducting a limited, voluntary recall due to Hospira Inc.'s ("Hospira") June 15, 2017 recall announcement that microbial growth was detected during a routine simulation of the manufacturing process and therefore there was a lack of sterility assurance. The products being recalled by PharMEDium Services were compounded using certain Hospira products. The recalled products are specific lots of Potassium Phosphate and Succinylcholine Chloride. This is a secondary recall based on a Hospira's recent recall: https://www.fda.gov/Safety/Recalls/ucm563383.htm.	Voluntary Recall
Potassium Phosphate	15 mMol Potassium Phosphate (Preservative Free) in 0.9% Sodium Chloride 250 mL in 250 mL Intravia Bag with Additive Cap	6/26/2017	PharMEDium Services is conducting a limited, voluntary recall due to Hospira Inc.'s ("Hospira") June 15, 2017 recall announcement that microbial growth was detected during a routine simulation of the manufacturing process and therefore there was a lack of sterility assurance. The products being recalled by PharMEDium Services were compounded using certain Hospira products. The recalled products are specific lots of Potassium Phosphate and Succinylcholine Chloride. This is a secondary recall based on a Hospira's recent recall: https://www.fda.gov/Safety/Recalls/ucm563383.htm.	Voluntary Recall
Potassium Phosphate	15 mMol Potassium Phosphate (Preservative Free) in 0.9% Sodium Chloride 150 mL in 150 mL Intravia Bag	6/26/2017	PharMEDium Services is conducting a limited, voluntary recall due to Hospira Inc.'s ("Hospira") June 15, 2017 recall announcement that microbial growth was detected during a routine simulation of the manufacturing process and therefore there was a lack of sterility assurance. The products being recalled by PharMEDium Services were compounded using certain Hospira products. The recalled products are specific lots of Potassium Phosphate and Succinylcholine Chloride. This is a secondary recall based on a Hospira's recent recall: https://www.fda.gov/Safety/Recalls/ucm563383.htm.	Voluntary Recall
Potassium Phosphate	15 mMol Potassium Phosphate (Preservative Free) in 0.9% Sodium Chloride 100 mL in 150 mL Intravia Bag	6/26/2017	PharMEDium Services is conducting a limited, voluntary recall due to Hospira Inc.'s ("Hospira") June 15, 2017 recall announcement that microbial growth was detected during a routine simulation of the manufacturing process and therefore there was a lack of sterility assurance. The products being recalled by PharMEDium Services were compounded using certain Hospira products. The recalled products are specific lots of Potassium Phosphate and Succinylcholine Chloride. This is a secondary recall based on a Hospira's recent recall: https://www.fda.gov/Safety/Recalls/ucm563383.htm.	Voluntary Recall
Potassium Phosphate	7.5 mMol Potassium Phosphate (Preservative Free) in 0.9% Sodium Chloride 100 mL in 150 mL Intravia Bag	6/26/2017	PharMEDium Services is conducting a limited, voluntary recall due to Hospira Inc.'s ("Hospira") June 15, 2017 recall announcement that microbial growth was detected during a routine simulation of the manufacturing process and therefore there was a lack of sterility assurance. The products being recalled by PharMEDium Services were compounded using certain Hospira products. The recalled products are specific lots of Potassium Phosphate and Succinylcholine Chloride. This is a secondary recall based on a Hospira's recent recall: https://www.fda.gov/Safety/Recalls/ucm563383.htm.	Voluntary Recall

Potassium Phosphate	7.5 mMol Potassium Phosphate (Preservative Free) in 5% Dextrose 100 mL in 150 mL Intravia Bag	6/26/2017	PharMEDium Services is conducting a limited, voluntary recall due to Hospira Inc.'s ("Hospira") June 15, 2017 recall announcement that microbial growth was detected during a routine simulation of the manufacturing process and therefore there was a lack of sterility assurance. The products being recalled by PharMEDium Services were compounded using certain Hospira products. The recalled products are specific lots of Potassium Phosphate and Succinylcholine Chloride. This is a secondary recall based on a Hospira's recent recall: https://www.fda.gov/Safety/Recalls/ucm563383.htm.	Voluntary Recall
Potassium Phosphate	15 mMo1 Potassium Phosphate (Preservative Free) in 5% Dextrose	6/26/2017	PharMEDium Services is conducting a limited, voluntary recall due to Hospira Inc.'s ("Hospira") June 15, 2017 recall announcement that microbial growth was detected during a routine simulation of the manufacturing process and therefore there was a lack of sterility assurance. The products being recalled by PharMEDium Services were compounded using certain Hospira products. The recalled products are specific lots of Potassium Phosphate and Succinylcholine Chloride. This is a secondary recall based on a Hospira's recent recall: https://www.fda.gov/Safety/Recalls/ucm563383.htm.	Voluntary Recall
Potassium Phosphate	40 mMol Potassium Phosphate (Preservative Free) in 0.9% Sodium Chloride 250 mL in 250 mL Intravia Bag	6/26/2017	PharMEDium Services is conducting a limited, voluntary recall due to Hospira Inc.'s ("Hospira") June 15, 2017 recall announcement that microbial growth was detected during a routine simulation of the manufacturing process and therefore there was a lack of sterility assurance. The products being recalled by PharMEDium Services were compounded using certain Hospira products. The recalled products are specific lots of Potassium Phosphate and Succinylcholine Chloride. This is a secondary recall based on a Hospira's recent recall: https://www.fda.gov/Safety/Recalls/ucm563383.htm.	Voluntary Recall
Potassium Phosphate	9 mMol Potassium Phosphate (Preservative Free) in 5% Dextrose 50 mL in 50 mL Intravia Bag	6/26/2017	PharMEDium Services is conducting a limited, voluntary recall due to Hospira Inc.'s ("Hospira") June 15, 2017 recall announcement that microbial growth was detected during a routine simulation of the manufacturing process and therefore there was a lack of sterility assurance. The products being recalled by PharMEDium Services were compounded using certain Hospira products. The recalled products are specific lots of Potassium Phosphate and Succinylcholine Chloride. This is a secondary recall based on a Hospira's recent recall: https://www.fda.gov/Safety/Recalls/ucm563383.htm.	Voluntary Recall
Succinylcholine Chloride	20 mg/mL Succinylcholine Chloride Injection (Preserved) 10 mL in 10 mL BD Syringe	6/26/2017	PharMEDium Services is conducting a limited, voluntary recall due to Hospira Inc.'s ("Hospira") June 15, 2017 recall announcement that microbial growth was detected during a routine simulation of the manufacturing process and therefore there was a lack of sterility assurance. The products being recalled by PharMEDium Services were compounded using certain Hospira products. The recalled products are specific lots of Potassium Phosphate and Succinylcholine Chloride. This is a secondary recall based on a Hospira's recent recall: https://www.fda.gov/Safety/Recalls/ucm563383.htm.	Voluntary Recall
Amitriptyline	25 mg Tablets	6/29/2017	This recall was issued due to the presence of an unrelated active ingredient, Imipramine, which was identified during routine testing.	Retail Level Recall
July				
NovoPen Echo, Insulin Pen Device	Insulin Pen Device	7/5/2017	Novo Nordisk has initiated a recall of insulin cartridge holders used in a small number of NovoPen Echo batches because they may crack or break if exposed to certain chemicals, such as cleaning agents	Consumer Level Recall
Lactulose	10 GM/15 mL, Oral Solution & 20 GM/30 mL Oral Solution	7/5/2017	This recall was issued because the drug product does not or may not meet the required Total Yeast/Mold Count specification of Not More Than 10 CFU/mL.	Retail Level Recall
Doxycycline Hyclate	25 g 500 cc, 100g 16 oz, 500g 2500 cc & 1,000g 1 gallon	7/5/2017	This recall was issued because the manufacturer and product were discovered to be on FDA Import Alert 66-66 for misbranding of active pharmaceutical ingredient.	Class II Recall
Buprenorphine & Naloxone	8/2 mg sublingual tablets, 2/0.5 mg sublingual tablets	7/5/2017	This recall was issued due to out-of-specification test results for related compounds largest unknown impurity.	Retail Level Recall
0.9 % Sodium Chloride Injection	100 mL VIAFLEX Plastic Container & 250 mL VIAFLEX Plastic Container	7/6/2017	Recall due to the potential presence of leaks. A leak of the solution bag may allow for delay or interruption of therapy, under-delivery, unintended drug exposure, and microbial contamination. If not detected, the use of a solution bag with a a leak could lead to a bloodstream infection or other serious adverse health consequences.	Consumer Level Recall

5% Dextrose Injection	100mL VIAFLEX Plastic Container Multi Pack	7/6/2017	Recall due to the potential presence of leaks. A leak of the solution bag may allow for delay or interruption of therapy, under-delivery, unintended drug exposure, and microbial contamination. If not detected, the use of a solution bag with a a leak could lead to a bloodstream infection or other serious adverse health consequences.	Consumer Level Recall
Potiga	50 mg, 200mg, 300mg, 400mg & 500 mg, 90 Count Tablets	7/11/2017	This recall was issued due to the discontinuation of the product due to limited usage.	Retail Level Withdrawal
Pravastatin DR	10 mg tablets 90 count, 10 mg tablets 500 count	7/12/2017	This recall was issued due to an out-of-specification result for Lot number C700220, 500 count, and out-of-trend result for Lot Number C700217, 90 count, observed for Related Substances during stability testing.	Retail Level Recall
Chlorhexidine Gluconate 0.12% Oral Rinse	473 mL	7/12/2017	This recall was issued due to CGMP Deviations.	Class II Recall
Opana ER	5mg, 7.5mg, 10mg, 15mg, 20mg, 30mg, and 40mg Tablets	7/12/2017	On July 12, 2017, Endo Pharmaceuticals announced that it has voluntarily agreed to discontinue its abuse-deterrent extended-release formulation of oxymorphone (Opana® ER) from the US market, about a month after the United States Food and Drug Administration (FDA) asked the company to stop selling the pain medication.	Voluntary Recall
Menveo Vaccine	Meningitis Vaccine	7/14/2017	This recall was issued due to the batch being subject to a mechanical intervention executed during the aseptic filling operations, which is not supported by validation data.	Retail Level Recall
MenA Lyophilized Component of Vaccine	MenA Lyophilized Component of Vaccine	7/14/2017	This recall was issued due to the batch being subject to a mechanical intervention executed during the aseptic filling operations, which is not supported by validation data.	Retail Level Recall
MenCYW	135 Liquid Component of Vaccine	7/14/2017	This recall was issued due to the batch being subject to a mechanical intervention executed during the aseptic filling operations, which is not supported by validation data.	Retail Level Recall
Atomic and Xplode Capsules	30 & 60 Count Bottles	7/24/2017	Corpus Christi, TX, EZ Weight Loss TX is voluntarily recalling all lots of La Bri's Body Health Atomic and Xplode capsules to the consumer level. FDA analysis has found the products to be tainted with sibutramine.	Voluntary Recall
All Sterile Drug Products		7/25/2017	Cantrell Drug Company is voluntarily recalling all lots of unexpired sterile drug products to the hospital and user level due to lack of sterility assurance. The recalled products were distributed to health care facilities nationwide, except to the states of Connecticut, Hawaii, South Carolina and Vermont.	Voluntary Recall
Cyclobenzaprine HCL and Amantadine HCL	USP 5 mg 50ct Unit Dose & USP 100 mg 50ct Unit Dose	7/27/2017	These products have been recalled due to a potential mislabeling. A small number of cartons containing Cyclobenzaprine HCl Tablets 5 mg UD Blister Cards may potentially be mislabeled as Amantadine HCl Capsules, USP 100 mg. The unit dose blisters inside the carton are correctly labeled as Cyclobenzaprine HCl Tablet, USP 5 mg.	Voluntary Recall
Famotidine	20mg tablets	7/27/2017	This recall was issued due to the potential of tablets exceeding weight specifications.	Retail Level Withdrawal
Cyclobenzaprine HCl Tablets	5mg tablets	7/28/2017	Apace Packaging announced a voluntary recall of one lot of Cyclobenzaprine HCl Tablets 5mg and one lot of Amantadine HCl Capsules 100mg due to a potential labeling error. A small number of cartons containing Cyclobenzaprine HCl Tablets 5mg may potentially be mislabeled as Amantadine HCl Capsules 100mg. The unit dose blisters in the cartons, however, are correctly labeled as Cyclobenzaprine HCl Tablets 5mg. The recall affects Cyclobenzaprine HCl 5mg, 50-count unit dose (Lot #16710) and Amantadine HCl 100mg, 50-count unit dose (Lot #16710).	Voluntary Recall
Amantadine HCl Capsules	100mg tablets	7/28/2017	Apace Packaging announced a voluntary recall of one lot of Cyclobenzaprine HCl Tablets 5mg and one lot of Amantadine HCl Capsules 100mg due to a potential labeling error. A small number of cartons containing Cyclobenzaprine HCl Tablets 5mg may potentially be mislabeled as Amantadine HCl Capsules 100mg. The unit dose blisters in the cartons, however, are correctly labeled as Cyclobenzaprine HCl Tablets 5mg. The recall affects Cyclobenzaprine HCl 5mg, 50-count unit dose (Lot #16710) and Amantadine HCl 100mg, 50-count unit dose (Lot #16710).	Voluntary Recall

One Lot of 0.9% Sodium Chloride Injection/ Hospira	1000mL Single Dose Flexible Container	7/28/2017 & 7/31/2017	CU Medical, Inc. is voluntarily recalling one lot of 0.9% Sodium Chloride Injection, USP 1000 mL to the hospital/user level due to a confirmed customer complaint of particulate matter identified as stainless steel within a single flexible container. From 7/31/2017 - This recall was issued due to a confirmed customer complaint of particulate matter identified as stainless steel within a single flexible container.	Voluntary Recall/ Hospital level Recall
Empty Intravia® Containers with non-DEHP fluid path	Empty Containers	7/28/2017	This recall was issued due to the potential presence of leaks. Leaks may allow for microbial contamination of the sterile fluid path. If not detected, using a bag with a leak could lead to a bloodstream infection or other serious adverse health consequences.	Consumer Level Recall
August				
Hydromorphone	10 mg/mL 50 mL single-dose vials, 10 mg/mL 5 mL single-dose vials, & 5 mL single-dose vials.	8/2/2017	This recall was issued due to visible particulates composed of silicone oil found within internal reserve samples.	Retail Level Recall
Diocto Liquid and Diocto Syrup/ Rugby	Liquid 50 mg/5 mL OR Syrup 60mg/15mL	8/2/2017	Rugby® Laboratories of Livonia, MI is voluntarily recalling all lots within the expiry of Diocto Liquid and Diocto Syrup, (docusate sodium solutions) manufactured by PharmaTech, LLC of Davie, FL due to a risk of product contamination with Burkholderia cepacia.	Voluntary Recall
Phentermine HCL	15 mg capsules, 100 count & 15 mg capsules 1,000 count	8/4/2017	This recall was issued due to out-of-specification results for individual unknown impurities at 30th month Room Temperature Retained Sample stability test for Phentermine HCL Capsules, USP 15 mg.	Retail Level Recall
GlipiZIDE	5 mg Extended-Release tablets	8/4/2017	This recall was issued due to out of specification test results for water content obtained during stability testing.	Retail Level Recall
Quillivant XR	600 mg 120 mL Oral Suspension, & 750 mg 150 mL Oral Suspension	8/7/2017	This recall was issued due to products from these lots not meeting the specification for dissolution.	Retail Level Recall
All liquid products manufactured by PharmaTech, and distributed by Leader Brand, Major Pharmaceuticals, and Rugby Laboratories	All liquid products manufactured by PharmaTech, and distributed by Leader Brand, Major Pharmaceuticals, and Rugby Laboratories	8/10/2017	FDA is announcing a voluntary recall of all liquid products manufactured by PharmaTech, and distributed by Leader Brand, Major Pharmaceuticals, and Rugby Laboratories, due to possible Burkholderia cepacia contamination. These products, including various drugs and dietary supplements intended for use in infants and children, were distributed nationwide. See the recall announcement for a complete list of recalled products with photos. (Drug List is in the below box.)	Voluntary Recall
Continued…	Continued…	Continued…	https://www.fda.gov/Safety/Recalls/ucm515610.htm	Continued…
Pravastatin Sodium Tablets USP	40mg Packaged in Bottles of 30 Tablets	8/9/2017	International Laboratories, LLC is voluntarily recalling one (1) Lot of Pravastatin Sodium Tablets USP 40 mg packaged in bottles of 30 tablets, to the consumer level due to mislabeling. The product is labeled as Pravastatin Sodium Tablets USP 40 mg but contained Bupropion Hydrochloride XL 300 mg tablets.	Voluntary Recall
Zatean Prenatal DHA capsules	label listing FD&C Yellow #6 instead of FD&C Yellow #5 as an excipient ingredient	8/14/2017	This recall was issued due to the label listing FD&C Yellow #6 instead of FD&C Yellow #5 as an excipient ingredient.	Retail Level Recall
Lorazepam Oral Concentrate	2mg/mL	8/15/2017	Amneal announced a voluntary recall of 13 lots of Lorazepam Oral Concentrate 2mg/mL due to an error in the dropper markings. The dosing droppers, supplied by a third party, were misprinted with the dose markings in reverse number, shifted dose markings or no dose markings.	Voluntary Recall
Vital Rx, Inc. d/b/a Atlantic Pharmacy and Compounding	All compounded injectable prescription medications	8/18/2017	Vital Rx, Inc. d/b/a Atlantic Pharmacy and Compounding is voluntarily recalling all lots of all compounded injectable prescription medications to the consumer level. The compounded injectable prescription medications have been found to lack sterility assurance. Atlantic Pharmacy and Compounding became aware of this issue during an FDA (Food and Drug Administration) inspection of the pharmacy.	Voluntary Recall
Ketorolac Tromethamine Injection, USP	30 mg/mL, 1 mL vial	8/17/2017	This recall was issued due to the presence of visible particulate in vials that has been identified as crystalline ketorolac calcium salt.	Retail Level Recall
Paroxetine	30mg Tablets	8/22/2017	This recall was issued based on two product complaints where the complainants found one or two pills of Zydus Risperidone Tablets USP, 0.25mg in a bottle of Zydus Paroxetine Tablets USP, 30mg.	Retail Level Recall
Ninjacof & Ninjacof A	473 mL bottles	8/22/2017	Centurion Labs is voluntarily recalling, as a precautionary measure, 1 lot of Ninjacof (Lot# 200N1601) and 1 lot of Ninjacof A (Lot# 201NA1601) manufactured by Vilvet (Dania Beach, FL) and distributed by Centurion Labs to the retail level due to potential contamination with Burkholderia cepacia.	Voluntary Recall

Levophed	1 mg/mL 4 mL Injection	8/23/2017	This recall was issued due to a potential lack of sterility assurance resulting from use of a damaged sterilizing filter for nitrogen used in the manufacturing process.	Retail Level Recall
Enalapril Maleate tablets	2.5mg & 5mg tablets	8/25/2017	This recall was issued due to Out of Specification reports related to Lot DR10635 and increased impurity levels on Lots DR10636 and DR10821.	Retail Level Recall
Vancomycin Hydrochloride for Injection	750 mg/vial	8/30/2017	The recall was due to a confirmed customer report for the presence of particulate matter, confirmed as glass, within a single vial.	Voluntary Recall
Piyanping Anti-Itch Lotion	Lotion	8/30/2017	The product was manufactured using the active pharmaceutical ingredient dexamethasone rather than hydrocortisone. Dexamethasone is not listed as an ingredient in the labeling.	Voluntary Recall
Enalapril Maleate tablets	5mg tablets	8/31/2017	This recall was issued due to increased impurity levels as compared to typical long-term stability results.	Retail Level Recall
September				
Propafenone HCL	150 mg Tablets	9/1/2017	This recall was issued due to the discovery of OOS (Out-Of-Specification for moisture content)	Retail Level Recall
Hydromorphone HCl Injection	(2 mg/mL) 1mg/mL Vial	9/1/2017	Hospira, Inc., a Pfizer company, is voluntarily recalling one lot of Hydromorphone HCl Injection, USP, CII (2 mg/mL) 1mg/mL Vial and four lots of Levophed® (Norepinephrine Bitartrate Injection, USP), 4 mg/4 mL (1 mg/mL) Vial due to a potential lack of sterility assurance resulting from use of a damaged sterilizing filter for nitrogen used in the manufacturing process.	Voluntary Recall
Levophed® (Norepinephrine Bitartrate Injection, USP	4 mg/4 mL (1 mg/mL) Vial	9/1/2017	Hospira, Inc., a Pfizer company, is voluntarily recalling one lot of Hydromorphone HCl Injection, USP, CII (2 mg/mL) 1mg/mL Vial and four lots of Levophed® (Norepinephrine Bitartrate Injection, USP), 4 mg/4 mL (1 mg/mL) Vial due to a potential lack of sterility assurance resulting from use of a damaged sterilizing filter for nitrogen used in the manufacturing process.	Voluntary Recall
Oxytocin compounded with Lactated Ringers and all unexpired lots of Oxytocin compounded with Lactated Ringers and Dextrose products	All products that were produced between July 6, 2017 and August 29, 2017	9/1/2017	Laboratory test results have indicated a lower than expected potency affecting certain lots which would lead to a lower dose being administered. An unexpected reduction in dose could lead to a delay in treatment, disruption of clinical care of the patient, and worsening of patient's conditions.	Voluntary Recall
Daytrana (Brand) Patches	10 mg/9 HR Patch, 15 mg/9 HR Patch, 20 mg/9 HR Patch, & 30 mg/9 HR Patch.	9/1/2017	This recall was issued due to the (6) six lots no longer meet the release liner removal specification and/or z-statistic.	Retail Level Recall
BD Insulin Syringes with the BD Ultra-FineTM needle	½ mL 12.7mm 30G	9/1/2017	This recall was issued because polybags in the lot were incorrectly labeled as BD Ultra-FineTM needle ½mL 8mm 31G, Cat (Ref) 328468.	Consumer Level Recall
Morphine Sulfate Oral Solution	100 mg/ 5 mL (20 mg/mL)	9/6/2017	This recall was issued due to a defective container resulting in the oral solution leaking from container.	Class II Recall
Acarbose	25 mg tablets	9/6/2017	This recall was issued due to an incorrect expiration date of July 2018 printed on the product labeling.	Retail Level Recall
Amoxicillin and Clavulanate Potassium for Oral Suspension	250/62.5 mg per 5 mL	9/6/2017	This recall was issued due to the presence of foreign substance. Customer complaint of blue foreign material identified as a portion of a nitrile glove was discovered in product.	Class II Recall
Activase® (Alteplase)	100 mg	9/6/2017	The vials of Sterile Water for Injection, manufactured by Hospira Inc., a Pfizer company, and packaged with Activase 100 mg, may be cracked or chipped at the neck of the vial and leaking	Voluntary Recall
Baby Organic Liquid supplement for infants	ALL	9/8/2017	The recall is being conducted as a precautionary measure because the product includes directions for use that may not be interpreted correctly.	Voluntary Recall

Diabetes Infusion Sets	Quick-set® Paradigm® Infusion Set MiniMed® mio® Infusion Set Silhouette® Paradigm® Infusion Set Sure-T® Paradigm® Infusion Set Quick-set® Luer Lock Infusion Set Silhouette® Luer Lock Infusion Set MiniMed™ Sure-T™ Infusion Set - Luer Lock	9/11/2017 **10/2/2017	Medtronic plc (NYSE:MDT) announced today that it has started to inform patients worldwide of a voluntary recall of specific lots of infusion sets used with all models of Medtronic insulin pumps. The recall is related to a certain discontinued component in these infusion sets and does not include insulin pumps or glucose sensors. The company determined, through recent field reports from patients and root cause analysis, that a component, the vent membrane, in the recalled infusion sets may be susceptible to being blocked by fluid during the process of priming/fill-tubing.	Voluntary Recall
Povidone Iodine Prep Solution	10% 1 gallon	9/13/2017	This recall was issued due to a label mix-up. Finished product Povidone iodine 7.5% was labeled as Povidone iodine 10%. The outer box had the correct label. This recall affects lot number 3A176011 exp. 10/18.	Class II Recall
Fosphenytoin Sodium	500 mg/10 mL single-dose vials	9/14/2017	This recall was issued due to the potential presence of particulate matter (sub-visible) associated with the active ingredient. This recall affects lot number AP160016 exp. 06/30/18.	Retail Level Recall
Procrit 10,000 U	1mL Vials	9/15/2017	This recall was issued due to the presence of barely visible thin glass flakes (lamellae).	Retail Level Recall
Magnesium Citrate Liquid	10oz	9/19/2017	This recall was issued due to out-of-specification results for magnesium oxide concentration, where the investigation did not conclusively invalidate the original results, potentially leading to inconsistencies in blend uniformity.	Retail Level Recall
Vitamin A&D Ointment Skin Protectant	0.18 oz, 5mg	9/20/2017	This recall was issued because the individual A&D ointment foil packets are incorrectly labeled as petroleum jelly. The boxes and outer case are correctly labeled as A&D ointment. This recall affects lot number A-K-8383.	Class II Recall
Magnesium Citrate Solution		9/21/2017	This recall was issued due to out-of-specification results for magnesium oxide concentration, where the investigation did not conclusively invalidate the original results, potentially leading to inconsistencies in blend uniformity.	Retail Level Recall
Procrit (epoetin alfa)	1mL single-dose, preservative-free solution	9/26/2017	Last month Janssen announced that it had initiated a recall of two separate Procrit lots (Lot#G290491A and Lot#G290491B). Administration of intravenous products that contain particulates could potentially lead to embolic, thrombotic, or other vascular events (ie, phlebitis), while foreign body granuloma, local injection site reactions, and increased immunogenicity is possible with subcutaneous administration.	Voluntary Recall
Diabetes Infusion Sets	Quick-set® Paradigm® Infusion Set MiniMed® mio® Infusion Set Silhouette® Paradigm® Infusion Set Sure-T® Paradigm® Infusion Set Quick-set® Luer Lock Infusion Set Silhouette® Luer Lock Infusion Set MiniMed™ Sure-T™ Infusion Set - Luer Lock	9/11/2017 **9/26/2017.	Medtronic plc (NYSE:MDT) announced today that it has started to inform patients worldwide of a voluntary recall of specific lots of infusion sets used with all models of Medtronic insulin pumps. The recall is related to a certain discontinued component in these infusion sets and does not include insulin pumps or glucose sensors. The company determined, through recent field reports from patients and root cause analysis, that a component, the vent membrane, in the recalled infusion sets may be susceptible to being blocked by fluid during the process of priming/fill-tubing.	Voluntary Recall
Ampicillin Sodium	500 mg 8 mL	9/26/2017	This recall was issued due to reports of missing labels on the product containers.	Retail Level Recall
October				
Carbamazepine Suspension	100 mg/5 mL Unit-Dose Cups	10/3/2017	This recall was issued due to the product being subpotent: out of specification at the six-month stability interval.	Retail Level Recall
Povidone Iodine Pads	Pads	10/3/2017	This recall was issued due to unmet iodine assay level requirements to support 36-month expiration dating.	Retail Level Recall
INTRALIPID 20% IV Fat Emulsion	100 mL	10/6/2017	The product has been exposed to subfreezing temperatures during transit to a distribution facility. The subfreezing temperature is outside of the acceptable storage range listed on the product labeling. Other shipments of this lot are not affected by this issue.	Voluntary Recall

Lorazepam	0.5 mg Tablets	10/6/2017	This recall was issued due to a complaint from a pharmacists regarding Lorazepam Tablets USP 0.5 mg. In one bottle, the label states 0.5 mg but the tablets inside are of Lorazepam Tablets USP 1 mg.	Retail Level Recall
Kogenate FS	3000 IU w/ Vial Adapter	10/11/2017	This recall was issued an excipient used in the manufacturing process was mislabeled.	Retail Level Recall
Sweetening Enhancer	1 oz & 4 oz	10/17/2017	This recall was issued as a result of subsequent testing of the product in our ongoing stability program which indicated that there were microbial growth.	Retail Level Recall
Bisoprolol	5 mg tablets	10/17/2017	This recall was issued for an unknown impurity observed during the 18-month stability testing.	Retail Level Recall
Octagam	10% 20GM Liquid Preparation	10/18/2017	This recall was issued as a result of an increased number of reports of hypersensitivity events.	Provider Level Recall
Methylphenidate	20 mg tablets	10/18/2017	This recall was issued due to dissolution results for immediate release that were below specification (out-of-specification) at the routing nine-month stability time-point.	Retail Level Recall
Clofarabine	20 mg/20 mL Injection	10/20/2017	This recall was issued because item/lot that was packed using the Clolar® injection package insert.	Retail Level Recall
Alprazolam	0.25 mg tablets	10/20/2017	This recall was issued due to an out-of-specification result for an unknown impurity during routine stability testing.	Retail Level Recall
Oralyte Solution	Grape Flavor, 33 ounce & Plus Zinc Unflavored 33 ounce	10/23/2017	This recall was issued due to a foreign object being found in a bottle of Rugby brand Pediatric electrolyte liquid.	Retail Level Recall
Activase	100 mg 100 mL vials	10/24/2017	This recall was issued due to the potential for faulty packaging of the product.	Retail Level Recall
Duloxetine DR capsules	20mg, 30mg and 60 mg capsules.	10/24/2017	This recall was issued due to an “Out of Spec” in stability testing with slightly elevated levels of phthalic acid.	Retail Level Recall
Eye Drops manufactured by Allergan	Combigan 0.2%/0.5% eye drops 5 mL, Combigan 0.2%/0.5% eye drops 10 mL, Lumigan 0.01 % eye drops 2.5 mL, Combigan 0.2%/0.5% eye drops 2.5 mL, Combigan 0.2%/0.5% eye drops 15 mL	10/24/2017	This recall was issued due to product sample testing results did not meet the regulatory specifications for individual and total impurities.	Retail Level Recall
Symbio Muc Eye	0.17 fl.oz. 5 mL bottles	10/25/2017	This recall was issued due to lack of assurance of sterility.	Retail Level Recall
Betadine Swabstick	200 count manufactured by Purdue	10/25/2017	This recall was issued due to physical swelling of the finished packaging on Betadine Swabstick single counts observed on retained samples.	Retail Level Recall
Dutasteride and Tamsulosin	0.5/0.4 mg capsules 30 count and 90 count	10/27/2017	This recall was issued due to out of specification dissolution results obtained during stability testing.	Retail Level Recall
Combigan (brimonidine tartrate, timolol maleate)	0.2%/0.5%, 5mL solution, 2.5mL solution, 10mL solution, 15mL solution	10/27/2017	Allergan has announced a voluntary recall of 7 lots of Combigan (brimonidine tartrate, timolol maleate) and 1 lot of Lumigan (bimatoprost) due to testing results not meeting the regulatory specifications for individual and total impurities. Combigan and Lumigan are ophthalmic solutions indicated for the treatment of glaucoma and ocular hypertension.	Voluntary Recall
Lumigan (bimatoprost)	0.01%, 2.5mL	10/27/2017	Allergan has announced a voluntary recall of 7 lots of Combigan (brimonidine tartrate, timolol maleate) and 1 lot of Lumigan (bimatoprost) due to testing results not meeting the regulatory specifications for individual and total impurities. Combigan and Lumigan are ophthalmic solutions indicated for the treatment of glaucoma and ocular hypertension.	Voluntary Recall
Zoloft	25 mg tablets	10/27/2017	This recall was issued because product from the affected lot has the potential for thicker (overweight) or thinner (underweight) tablets, which would exceed specification.	Retail Level Recall
Diphenoxylate/Atropine	2.5 mg tablets 1000 count & 100 count	10/30/2017	This recall was issued because product from the affected lots has the potential for thicker (overweight) and thinner (underweight) tablets, which would exceed specification.	Retail Level Recall
November				
INTRALIPID 20% IV Fat Emulsion	100 mL	11/1/2017	The product has been exposed to subfreezing temperatures during transit to a distribution facility. The subfreezing temperature is outside of the acceptable storage range listed on the product labeling. Other shipments of this lot are not affected by this issue.	Class 1 Recall
Midazolam Injection, USP	2 mg/2 mL packaged in a 2 mL prefilled single-use glass syringe & 1 mg/mL 2 mL prefilled syringes	11/3/2017	The product mislabeled as Midazolam Injection, USP, 2 mg/2 mL contains syringes containing and labeled as Ondansetron Injection, USP, 4 mg/2 mL.	Voluntary Recall

Unifine Pentips	5 mm 31 G, 30 count and 100 count	11/7/2017	This recall was issued due to the potential of the lot being compromised by water in end user level packaging.	Consumer Level Recall
Ciprofloxacin	2 mg/mL 100 mL I.V. Bags	11/7/2017	This recall was issued due to out-of-specification test results for the batches at 18 months.	Retail Level Recall
Clozapine	100 mg Tablets	11/10/2017	This recall was issued due to potential presence of broken tablets.	Retail Level Recall
Nexterone Injection (amiodarone HCl)	150 mg/100 mL Premixed Injection	11/15/2017	Baxter International Inc. announced today it is voluntarily recalling one lot of NEXTERONE (amiodarone HCl) 150 mg/100 mL Premixed Injection – distributed between 6/23/2017 and 10/2/2017 in the United States to wholesalers/distributors and healthcare facilities – due to the potential presence of particulate matter. The particulate matter may have entered the solution during the manufacturing process.	Voluntary Recall
Chewable Aspirin	81 mg	11/16/2017	This recall was issued due to a stability test result which did not meet predefined specifications.	Retail Level Recall
Diphenoxylate Hydrochloride and Atropine Sulfate Tablets	2.5 mg/0.025 mg, 100 tablet count and 1000 tablet count bottles	11/17/2017	For Immediate Release – PEAPACK, NJ, November 16, 2017 - Greenstone LLC, a wholly owned subsidiary of Pfizer Inc., is voluntarily recalling multiple lots of diphenoxylate hydrochloride and atropine sulfate tablets, USP to the consumer level. Greenstone initiated this recall because product from these lots has the potential to be super potent or sub potent.	Voluntary Recall
Pravastatin Sodium	40 mg tablets	11/20/2017	This recall was issued due to a pharmacy complaint where one Duloxetine Delayed Capsule, 30mg was found in Pravastatin Sodium Tablets USP, 40mg bottle. As a result of this, if the patient accidently consumes the Duloxetine Delayed Release Capsule USP 30mg, it is unlikely to result in any serious adverse event(s). The patient on the treatment of Pravastatin Sodium tablets USP 40mg should be able to identify Duloxetine Delayed Release Capsules 30mg because both products are different dosage forms and have distinct descriptions.	Retail Level Recall
Paroxetine	30 mg Tablets, 30 count, 500 count, and 1000 count	11/21/2017	This recall was issued based on complaint received of potential mix up of foreign tablet.	Retail Level Recall
Povidone Iodine Prep Pads	Prep Pads	11/21/2017	This recall was issued due to unmet iodine assay level requirements to support 36-month expiration dating.	Retail Level Recall
Amethyst	90/20 mcg tablets	11/21/2017	This recall was issued due to an incorrect description printed on the blister foil and package insert, stating “Tablets in week 4 are inactive.” However, each blister foil unit contains 28 active tablets.	Retail Level Recall
Sodium Chloride Injection	0.9 % 100 mL	11/22/2017	This recall was issued due to reports of individual bags of the product code and lot number listed above as being adhered together.	Retail Level Recall
Mometasone Furoate	0.1 % cream	11/21/2017	This recall was issued based on some market complaints received indicating that this specific lot of this product was found to have a “gritty texture”.	Retail Level Recall
Riomet (Metformin Hydrochloride Oral Solution)	Oral Solution	11/27/2017	Sun Pharmaceutical Industries is recalling two lots of Riomet (Metformin Hydrochloride Oral Solution), which were found to be contaminated with Scopulariopsis brevicaulis. Use of the affected Riomet potentially could result in a risk of infection, especially in the immunocompromised patient. The most plausible portal of entry of Scopulariopsis brevicaulis is the respiratory tract, where it may cause pneumonia, sinusitis and disseminated infections.	Retail Level Recall
Limbrel	Capsules	11/21/2017	On November 21, 2017, the United States Food and Drug Administration (FDA) issued a MedWatch stating they are investigating serious adverse events involving Limbrel capsules, a product in capsule form currently being marketed as a medical food to manage the metabolic processes associated with osteoarthritis. While a range of adverse events have been reported, two serious and potentially life-threatening medical conditions are among them: drug-induced liver injury and hypersensitivity pneumonitis. In total, the FDA has received 194 adverse event reports regarding Limbrel, of those, 57 of the cases contained sufficient information to analyze in detail whether Limbrel was associated with an adverse event; 30 of these contained sufficient information to use the Council for International Organizations of Medical Sciences (CIOMS) causality assessment method to determine the likelihood that an association between the consumption of Limbrel and the adverse events reported exists.	Retail Level Recall
Lorazepam	0.5 mg Tablets	11/28/2017	This recall was issued due to a complaint of Product Mix-Up.	Retail Level Recall
Venlafaxine	37.5 mg Tablets	11/28/2017	This withdrawal was issued due to a limited issue of a typographical error, and restricted to the bottle label claim, while all details such as generic name, strength, NDC number, storage condition, and count are correct.	Retail Level Recall

Paroxetine	30 mg Tablets	11/29/2017	This recall was issued due to the presence of foreign tablets/capsules.	Class II Recall
TYVASO (treprostinil)	Inhalation Solution Treprostinil 1.74 mg/2.9 mL (0.6 mg/mL)	11/29/2017	This recall was issued due to cGMP Deviations.	Class II Recall
Urin D/S	Tablets	11/29/2017	This recall was issued FDA analysis found this product to be Out of Specification for assay which could result in either Subpotent and/or Superpotent tablets.	Class II Recall
Penicillin v Potassium	125 mg Oral Solution 100 mL	11/30/2017	This recall was issued due to out of specification test results obtained for individual and total impurities during routine stability testing activities.	Retail Level Recall
December				
Valsartan	160 mg Tablets	12/1/2017	This recall was issued due to some tablets in the same bottle having different thickness.	Retail Level Recall
Pharmacist Choice Alcohol Prep Pads	By Simple Diagnoistics	12/5/2017	Simple Diagnostics is voluntarily recalling three lots of Pharmacist Choice Alcohol Prep Pads (UPC # 898302001050, NDC # 98302-0001-05), which were manufactured by Foshan Flying Medical Products Co. Ltd., located in China, due to the lack of sterility assurance and other quality issues.	Retail Level Recall
Viokace	20,880-78,300 tablets T	12/5/2017	This recall was issued due to product stability testing results did not meet the specifications for enzyme profile	Retail Level Recall
Raplixa Delivery Kit		12/6/2017	This recall was issued due to the filter in the insufflation filter assembly not meeting claims made in the device's 510(k) premarket notification. This recall affects all lot numbers of this product.	Retail Level Recall
Clolar	20mL single-dose vial	10/20/2017 dated 12/11/2017	This recall was issued because item/lots that were packed using the Clofarabine injection (authorized generic) package insert.	Retail Level Recall
Meclizine	12.5 mg Tablets	12/8/2017	This recall was issued due to shipment of bottles to customers prior to the approved wait period for FDA CBE-30 supplement filling.	Retail Level Recall
Synvisc-One	Synvisc-One	12/13/2017	This recall was issued due to an ongoing investigation in which subsequent investigational testing revealed the presence of microbial contamination.	Retail Level Recall
BD Precision Glide Needle	18G x 1 RB	12/13/2017	This recall was issued due to hub damage resulting in breakage and/or leakage during use.	Class II Recall
Moexipril Hydrochloride & Hydrochlorothiazide	7.5 mg/12.5 mg tablets	12/15/2017	This recall was issued due to an out of specification test result for the Moexipril Diketopiperazine impurity obtained during routine stability testing activities.	Retail Level Recall
Enoxaparin	Injection 120 mg/0.8 mL	12/15/2017	This recall was issued because the affected lot of 120mg/0.8mL was found to contain a single syringe of 150mg/1.0mL product in the 120mg/0.8mL blister. Use of this product does not represent any potential health hazard as the label on all syringes displays the correct dosage, and because the syringes display graduation marks to ensure correct dosing.	Retail Level Recall
Gabapentin	250 mg/5 mL Oral Soluti	12/19/2017	This recall was issued due to inadvertent release of a drug product with unapproved active ingredient manufacturer for this regulatory filing.	Retail Level Recall
INFeD	50 mg/mL 2 mL vials	12/19/2017	This recall was issued due to product stability testing results not meeting specifications for iron content	Retail Level Recall
Pantoprazole Sodium	Injection 40 mg per vial	12/19/2017	The product was found to contain glass particles in the vial. This problem was discovered as a result of a product complaint in which the contents of one vial from one batch was found to contain a piece of glass.	Voluntary Recall - Hospital Level
Codeine/Guaifen	10-100 mg/5 mL Solutio	12/21/2017	This recall was issued due to potential contamination of B. cepacia.	Retail Level Recall
Linezolid	600 mg/300 mL IV soluti	12/22/2017	This recall was issued because the contents of one bag was found to contain white particulate matter that has been identified as mold.	Retail Level Recall

Various BANDAID Products manufactured by Johnson & Johnson	BANDAID FA HURTFREE WRP1X2.3YD, BANDAID FA HURTFREE WRP2X2.3YD, BANDAID FA SECURFLX WRP2X2.5YD, BANDAID FA SECURFLX WRP3X2.5YD, COACH SPORTS WRAP, COACH SPORTS WRAP	12/22/2017	This recall was issued due to the current label stating, "not made with natural rubber latex" which needs to be updated based on recent awareness that natural latex was used as a base ingredient in the early-stage manufacturing process, which reduces the allergic protein found in natural latex.	Retail Level Recall
Vancomycin Hydrochloride Injection	Injection 750 mg/vials	12/27/2017	This recall was issued due to a confirmed customer report for the presence of particulate matter, confirmed as glass, within a single vial.	Class 1 Recall
0.25% Acetic Acid Irrigation	500 mL Plastic Irrigation	12/27/2017	This recall was issued due to the presence of particulate matter identified as polyethylene, which is consistent with the material used to manufacture the contain cap.	Class 2 Recall
Maximum Strength Zephrex-D	30 mg Nasal Decongesta	12/27/2017	This recall was issued due to microbial contamination of non-sterile products.	Class 2 Recall
Travasol 10 %	2000 mL	12/29/2017	This safety alert issued due to a customer complaint for the product code and lot number regarding one solution bag of 20% PROSOL injection which was found inside a 10% TRAVASOL injection over-pouch.	Retail-level Safety Alert
Levetiracetam	100mg/mL Oral Solution	12/29/2017	This recall was issued due to the presence of a foreign substance.	Retail Level Recall
PharMEDium Services, LLC - Various Drug Products to the Hospital/User Level	2 mcg/mL Fentanyl Citrate and 0.2% Ropivacaine HCl (Preservative Free) in 0.9% Sodium Chloride, 2 mcg/mL Fentanyl Citrate and 0.2% Ropivacaine HCl (Preservative Free) in 0.9% Sodium Chloride, 2 mcg/mL Fentanyl Citrate and 0.15% Ropivacaine HCl (Preservative Free) in 0.9% Sodium Chloride, 1 mg/mL Morphine Sulfate in 0.9% Sodium Chloride, 1 mg/mL Morphine Sulfate (Preservative Free) in 0.9% Sodium Chloride, 1 mg/mL HYDROmorphone HCl in 0.9% Sodium Chloride, 2 mcg/mL Fentanyl Citrate and 0.125% Bupivacaine HCl (Preservative Free) in 0.9% Sodium Chloride, 20 mg/mL Succinylcholine Chloride Injection (Preserved) Kit Check Tagged, 2 mcg/mL Fentanyl Citrate and 0.1% Bupivacaine HCl (Preservative Free) in 0.9% Sodium Chloride, 0.125% Bupivacaine HCl (Preservative Free) in 0.9% Sodium Chloride, 0.2 mg/mL	12/27/2017	PharMEDium Services, LLC (PharMEDium) is voluntarily recalling the below lots of drug products to the hospital/user level due to a lack of assurance of sterility.	Voluntary Recall - Nationwide